Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter … Read more
Market Cap & Net Worth: Procter & Gamble Health Limited (PGHL)
Procter & Gamble Health Limited (NSE:PGHL) has a market capitalization of $946.81 Million (₹82.00 Billion) as of March 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #10780 globally and #453 in its home market, demonstrating a 1.07% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Procter & Gamble Health Limited's stock price ₹4939.80 by its total outstanding shares 16599382 (16.60 Million).
Procter & Gamble Health Limited Market Cap History: 2015 to 2026
Procter & Gamble Health Limited's market capitalization history from 2015 to 2026. Data shows growth from $118.93 Million to $946.81 Million (21.70% CAGR).
Index Memberships
Procter & Gamble Health Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$539.70 Billion | 0.08% | #263 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.35 Trillion | 0.03% | #385 of 750 |
Weight: Procter & Gamble Health Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Procter & Gamble Health Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Procter & Gamble Health Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
Procter & Gamble Health Limited's market cap is 0.08 times its annual revenue
1.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.40x
Procter & Gamble Health Limited's market cap is 0.40 times its annual earnings
9.89x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $154.73 Million | $9.93 Billion | $791.30 Million | 0.02x | 0.20x |
| 2017 | $203.97 Million | $6.98 Billion | $939.10 Million | 0.03x | 0.22x |
| 2018 | $490.58 Million | $8.49 Billion | $8.39 Billion | 0.06x | 0.06x |
| 2019 | $768.41 Million | $8.89 Billion | $1.66 Billion | 0.09x | 0.46x |
| 2020 | $1.21 Billion | $10.09 Billion | $1.77 Billion | 0.12x | 0.68x |
| 2020 | $1.21 Billion | $11.55 Billion | $2.05 Billion | 0.10x | 0.59x |
| 2021 | $961.79 Million | $11.14 Billion | $1.93 Billion | 0.09x | 0.50x |
| 2022 | $720.88 Million | $12.30 Billion | $2.29 Billion | 0.06x | 0.31x |
| 2023 | $928.89 Million | $11.51 Billion | $2.01 Billion | 0.08x | 0.46x |
| 2024 | $1.00 Billion | $12.18 Billion | $2.51 Billion | 0.08x | 0.40x |
Competitor Companies of PGHL by Market Capitalization
Companies near Procter & Gamble Health Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Procter & Gamble Health Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Procter & Gamble Health Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Procter & Gamble Health Limited's market cap moved from $118.93 Million to $ 946.81 Million, with a yearly change of 21.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹946.81 Million | -13.38% |
| 2025 | ₹1.09 Billion | +8.88% |
| 2024 | ₹1.00 Billion | +8.08% |
| 2023 | ₹928.89 Million | +28.86% |
| 2022 | ₹720.88 Million | -25.05% |
| 2021 | ₹961.79 Million | -20.39% |
| 2020 | ₹1.21 Billion | +57.23% |
| 2019 | ₹768.41 Million | +56.63% |
| 2018 | ₹490.58 Million | +140.52% |
| 2017 | ₹203.97 Million | +31.82% |
| 2016 | ₹154.73 Million | +30.11% |
| 2015 | ₹118.93 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Procter & Gamble Health Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $946.81 Million USD |
| MoneyControl | $946.81 Million USD |
| MarketWatch | $946.81 Million USD |
| marketcap.company | $946.81 Million USD |
| Reuters | $946.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.